López-Gómez Victoria, Yarza Ramón, Muñoz-González Héctor, Revilla Enrique, Enrech Santos, González-Valle Olga, Tolosa Pablo, Ciruelos Eva
Department of Clinical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
Department of Dermatology, University Hospital 12 de Octubre, Madrid, Spain.
J Breast Cancer. 2019 Dec;22(4):661-666. doi: 10.4048/jbc.2019.22.e44.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis belong to a severe dermatopathic spectrum that includes frequently fatal mucocutaneous manifestations consisting of whole epidermal necrosis and sloughing with bullous transformation, blistering, and further skin detachment. Notably, cancer patients are at higher risk of developing SJS than the general population as a consequence of both the nature of neoplastic disease and frequent exposure to anticancer drugs. Ribociclib is a newly approved cycline-dependent kinase inhibitor that has been recently associated with a single case of SJS. We hereby present a case of ribociclib-related SJS. Early detection of threatening skin lesions is crucial to permit the immediate discontinuation of ribociclib given the predictable and unacceptable risk level. In cases of established SJS, early aggressive support should be initiated, ribociclib should be abruptly discontinued, and specific treatment based on actual evidence should be started.
史蒂文斯-约翰逊综合征（SJS）和中毒性表皮坏死松解症属于严重的皮肤病范畴，常伴有致命的黏膜皮肤表现，包括全层表皮坏死、大疱性转化、水疱形成以及进一步的皮肤脱落。值得注意的是，由于肿瘤疾病的性质以及频繁接触抗癌药物，癌症患者发生SJS的风险高于普通人群。瑞博西尼是一种新批准的细胞周期蛋白依赖性激酶抑制剂，最近有报道其与1例SJS病例相关。我们在此报告1例与瑞博西尼相关的SJS。鉴于风险水平可预测且不可接受，早期发现有威胁的皮肤病变对于立即停用瑞博西尼至关重要。对于确诊的SJS病例，应尽早开始积极支持治疗，立即停用瑞博西尼，并根据实际证据启动特异性治疗。
